Sponsors appearing before FDA advisory committees should be prepared to take a public vow promising to withdraw an accelerated approval drug or indication if a subsequent confirmatory trial fails to verify the expected magnitude of benefit.
AstraZeneca PLC was the latest sponsor to face scrutiny from the Oncologic Drugs Advisory Committee over future withdrawal plans for a drug under consideration
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?